Hims House Ep 39 - Legendary Wall Street analyst David Maris on why Hims could be massive—and what could go wrong
12 snips
Jul 22, 2025 David Maris, a renowned Wall Street analyst and founder of Wall Street Beats, discusses his bullish outlook on Hims, highlighting its growth potential and recent acquisition of ZAVA. He dives into the implosion of its partnership with Novo Nordisk and the associated legal risks. Maris shares insights on Hims' expansion into Canada and its potential to become a comprehensive healthcare platform. He also examines the market dynamics of GLP-1 treatments and the implications of high short interest on Hims' stock valuation.
AI Snips
Chapters
Transcript
Episode notes
Canada Expansion Makes Strategic Sense
- HIMS expansion into Canada is easier operationally due to cultural and time zone similarities.
- It offers experience in sourcing generics ahead of the US patent expiry, providing a competitive edge.
Novo Partnership Failed From Miscommunication
- The implosion of the Novo partnership likely stemmed from a lack of clear contractual boundaries and possible personality clashes.
- It wasn't a calculated sabotage but an unfortunate communication and execution failure.
Future GLP-1 Market Outlook
- Three years from now, the GLP-1 market will resemble today's with Lilly gaining more share and Novo losing ground.
- The introduction of generics will change dynamics drastically, making cheap generics the first-line treatment.